{"disease":{"id":"gastrointestinal-stromal-tumor","name":"Gastrointestinal stromal tumor","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":8,"pipeline_drug_count":0,"trial_count":14},"drugs":{"marketed":[{"drug_id":"regorafenib","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stivarga","generic_name":"regorafenib","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Bifunctional epoxide hydrolase 2","drug_class":"Kinase Inhibitor","quality_score":86,"revenue":"400","mechanism":"Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis."},{"drug_id":"pimitespib","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jeselhy","generic_name":"Pimitespib","company_name":"Taiho Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Heat shock protein HSP 90-beta","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sunitinib-malate","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"sunitinib","indication_name":"Gastrointestinal Stromal Tumor (GIST)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sutent","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"imatinib","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"avapritinib","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ayvakit","generic_name":"AVAPRITINIB","company_name":"Blueprint Medicines","drug_phase":"marketed","molecular_target":"Platelet-derived growth factor receptor alpha","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ayvakit works by blocking the activity of the PDGFRA protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"gleevec","indication_name":"Gastrointestinal stromal tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT04181970","title":"Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT03602092","title":"Observational Registry Data on GIST Patients","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT05400018","title":"Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1041,"lead_sponsor_name":"Genetron Health","has_results":false},{"nct_id":"NCT07273045","title":"A Comprehensive, Multinational GIST Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Universität Duisburg-Essen","has_results":false},{"nct_id":"NCT03471273","title":"Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal Tumor","phase":"NA","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT05565066","title":"A Real-world Comparison of FNB and FNA in IHC-required Lesions.","phase":"","overall_status":"COMPLETED","enrollment_count":439,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04557969","title":"Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":322,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05697107","title":"Ripretinib in Chinese Patients With Advanced GIST: a Real World Study","phase":"","overall_status":"UNKNOWN","enrollment_count":308,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT07454967","title":"Development of a Multimodal AI System for GIST Management","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT04143048","title":"A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05489237","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":278,"lead_sponsor_name":"IDRX, Inc., a wholly owned subsidiary of GSK, LLC","has_results":false},{"nct_id":"NCT05751733","title":"Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST","phase":"NA","overall_status":"RECRUITING","enrollment_count":258,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT07379047","title":"A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":255,"lead_sponsor_name":"Ningbo Newbay Technology Development Co., Ltd","has_results":false},{"nct_id":"NCT03114319","title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01271712","title":"Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05938309","title":"A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT01178307","title":"Symptom Inventory for Gastrointestinal Stromal Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":187,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04409223","title":"Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":185,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05197933","title":"Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach","phase":"NA","overall_status":"UNKNOWN","enrollment_count":182,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03139487","title":"A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":176,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06628739","title":"Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07411118","title":"RCT of EFTR Versus STER for GIST Treatment","phase":"NA","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06321055","title":"An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03353753","title":"Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Deciphera Pharmaceuticals, LLC","has_results":true},{"nct_id":"NCT04000529","title":"Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":122,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04933669","title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT01275222","title":"Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04633122","title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":true},{"nct_id":"NCT05440357","title":"Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Xinhua Zhang, MD","has_results":false},{"nct_id":"NCT06772233","title":"A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06748690","title":"MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT","phase":"NA","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03404076","title":"Unifying Advanced Treatment With Advanced Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Heidelberg University","has_results":false},{"nct_id":"NCT00867113","title":"Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03601234","title":"Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT02452424","title":"A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT05464875","title":"A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Xinhua Zhang, MD","has_results":false},{"nct_id":"NCT05461664","title":"Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA","phase":"","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Xinhua Zhang, MD","has_results":false},{"nct_id":"NCT01933958","title":"Regorafenib Post-marketing Surveillance in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01738139","title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06805825","title":"A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Novelty Nobility, Inc.","has_results":false},{"nct_id":"NCT04254939","title":"A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false},{"nct_id":"NCT00028002","title":"Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05665868","title":"Study on Integrated Nursing Strategy for Patients With Gastrointestinal Stromal Tumors After Targeted Therapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT05381753","title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","phase":"","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false}],"total":50},"guidelines":[{"drug_id":"sutent","guideline_body":"FDA label","recommendation":"Sunitinib malate is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sutent","guideline_body":"FDA label","recommendation":"Sunitinib malate is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sutent","guideline_body":"FDA label","recommendation":"Sunitinib malate is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sunitinib-malate","guideline_body":"FDA label","recommendation":"Sunitinib malate is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sunitinib-malate","guideline_body":"FDA label","recommendation":"Sunitinib malate is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sunitinib-malate","guideline_body":"FDA label","recommendation":"Sunitinib malate is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}